Formulation of an oral gel with antimicrobial activity against recurrent aphthous stomatitis, indicating effective natural remedies.
Background: Recurrent aphthous stomatitis (RAS) is an ulcerative disease with unclear etiopathogenesis. Microbial agents are suggested as one of the predisposing factors. Cassia fistula and Rosa x damascena are two plant species with antimicrobial properties that are widely used for medicinal purposes. Objectives: The aim of the present study was to formulate and evaluate the antimicrobial activity of an oral gel consisting of C. fistula extract (Ex) and R. x damascena essential oil (EO) for the treatment of RAS. Methods: Cassia fistula Ex was prepared by the maceration method, and then the phenolic content was measured using the Folin-Ciocalteu reagent. The hydrodistillation method was used to prepare R. x damascena EO, and its ingredients were analyzed by gas chromatography-mass spectrometry (GC/MS). The antimicrobial activity of Ex, EO, Ex/EO, and the gel formulation was evaluated using disk diffusion and microbroth dilution methods against three strains: Streptococcus mutans, Actinomyces viscosus, and Candida albicans. Carbomer 940, carboxymethyl cellulose, and hydroxypropyl methyl cellulose polymers were combined with Ex/EO, and then the physicochemical parameters were checked. Results: Extract, EO, Ex/EO, and gel formulations each showed the highest and lowest inhibitory effect against C. albicans and A. viscosus, respectively. The antimicrobial potential of Ex and EO was dose-dependent, but no statistically significant difference was observed between two concentrations of 1.9 - 1.7% in Ex and 0.7 - 0.9% in EO (P < 0.05). The highest antimicrobial capacity belonged to the combination of 1.7% and 0.7% concentrations of Ex and EO. Carbomer 940 in combination with Ex/EO (1.7/0.7%) was identified as the optimal formulation. Conclusions: The Carbomer 940 gel formulation, with a uniform appearance without bubbles or lumps, a pH equal to 6.87 ± 0.04, good viscosity, an expiration date of 65 days, and acceptable antimicrobial activity, was considered the approved formulation in this study.
No takes yet. Share an insight, caveat, or question.
Salimi et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: